Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

Risdiplam

Other names: RG7916; RO7034067

Modality: SMN2 Pre-mRNA Splicing Modifier

Disease State: Spinal Muscular Atrophy (SMA)

Summary

Risdiplam is an investigational survival motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.1 Ongoing clinical studies will further evaluate long-term benefits, real-world effectiveness, and optimal place in therapy alongside existing treatment options.

Clinical Trials

Risdiplam
NCT ID Study Phase Enrollment Status Study Title
NCT03779334 Phase II Active, not recruiting A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
NCT05861999 Phase IV Active, not recruiting A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
NCT05861986 Phase IV Active, not recruiting A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

Proposed Mechanism of Action

Selective SMN2 splicing modifier designed to bind with specificity to SMN2 pre-mRNA and promote inclusion of exon 7, thus increasing the production of functional SMN protein. It penetrates the blood-brain barrier providing  systemic distribution.2-4

Risdiplam is proposed to have a high specificity for SMN2 pre-mRNA2,4

  • The proposed mechanism of action for risdiplam is based on studies with small molecules closely related to risdiplam2,4
  • Risdiplam is proposed to bind to 2 sites on SMN2 pre-mRNA2:
    • 5' splice site (5'ss) of intron 7
    • Exonic splicing enhancer 2 (ESE2) in exon 7 
  • Binding to the 5’ss of intron 7 improves recognition by the U1 snRNP, promoting inclusion of exon 72
  • The unique specificity of 2 pre-mRNA binding sites increases levels of full-length SMN mRNA and protein while reducing the impact on splicing of other pre-mRNA2-4
  1. Roche. Product development pipeline. Roche. January 29, 2026. Accessed February 8, 2026. https://www.roche.com/​solutions/​pipeline
  2. Sivaramakrishnan M, McCarthy KD, Campagne S, et al. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat Commun. 2017;8(1):1476. doi:10.1038/​s41467-017-01559-4
  3. Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915-923. doi:10.1056/​NEJMoa2009965
  4. Mercuri E, Baranello G, Boespflug-Tanguy O, et al. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol. 2023;30(7):1945-1956. doi:10.1111/​ene.15499
  5. Swoboda KJ. Of SMN in mice and men: a therapeutic opportunity. J Clin Invest. 2011;121(8):2978-2981. doi:10.1172/​JCI58752

Looking for more information?

Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT

  • 5'ss
    5' splice site

  • ESE2
    Exonic splicing enhancer 2

  • SMA
    Spinal muscular atrophy

  • SMN
    Survival motor neuron

  • SMN2
    Survival motor neuron 2

  • mRNA
    Messenger RNA

  • snRNP
    Small nuclear ribonucleoproteins

+